Clinical Research, Pharma & Healthcare FinancingYolTech Reports Positive Interim Data on YOLT-202Business WireFebruary 23, 2026February 24, 2026 by Business WireFebruary 23, 2026February 24, 2026030 Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with...
